Volume 3, Issue 3 (12-2016)                   nbr 2016, 3(3): 258-268 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rezaee M, Baghbani Arani F, Arabi Mianroodi R. Point mutation in amino acid 263 of streptokinase gene as well as cloning and expression of the cysteine containing mutated protein. nbr. 2016; 3 (3) :258-268
URL: http://nbr.khu.ac.ir/article-1-2689-en.html
Abstract:   (4987 Views)

Streptokinase is one of the best known thrombolytic agents with widespread clinical use. However, its use is not risk-free due to its immunogenicity, hemorrhagic complications and relatively short half-life in circulation. Specific PEGylation of cysteine residue is a useful technique for reducing most of these complications. The aim of this study was designing and producing a cysteine containing mutant of streptokinase, to be used for specific PEGylation. Glut-amic acid 263, which is a surface amino acid in the structure of streptokinase protein, was selected for replacement with cysteine amino acid by site directed mutagenesis. The Glu263 codon was changed to cysteine codon by SOEing PCR technique. Then, the intact and mutated streptokinase genes were inserted into expression vector pET-26b (+). The co-nstructs were transformed to Escherichia.coli Rosetta (DE3) strain and the proteins were expressed by IPTG induction. The proteins were confirmed by SDS-PAGE and western blot analysis, purified by Ni-NTA agarose affinity chroma-tography under denaturing condition with urea and Sephadex G-25 column was applied to remove urea to refold the pr-oteins. This study indicated that by using aforesaid vector and host, cysteine containing mutant gene is expressed well and it will be appropriate for specific PEGylation.

Full-Text [PDF 572 kb]   (1519 Downloads)    
Type of Study: Original Article | Subject: Genetics
Received: 2016/02/16 | Revised: 2021/05/22 | Accepted: 2016/09/4 | Published: 2016/12/5 | ePublished: 2016/12/5

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Nova Biologica Reperta

Designed & Developed by : Yektaweb